Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct Phase Ib/II clinical trials for HLX701 in combination with Cetuximab and chemotherapy for advanced colorectal cancer [1] Group 1: Clinical Trial Approval - The approval allows for the clinical trials of HLX701 to be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - HLX701 is a recombinant human SIRPα-IgG4 Fc fusion protein injection [1] Group 2: Licensing and Development - HLX701 was licensed from FBD Biologics Limited in June 2025, granting exclusive rights for development, production, and commercialization in specified regions including mainland China, Hong Kong, Macau, Southeast Asia, the Middle East, and North Africa [1] - As of December 2025, the cumulative R&D investment for HLX701 by the group is approximately RMB 76.09 million, which includes licensing fees [1] Group 3: Market Context - As of the announcement date, there are no approved targeted CD47 SIRPα-Fc fusion proteins available globally [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for the clinical trial application of HLX701 in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer, indicating a significant step forward in its clinical development pipeline [1] Group 1: Product Development - HLX701 is a recombinant SIRPα-IgG4Fc fusion protein licensed from FBD Biologics Limited, intended for the treatment of various advanced solid tumors [1] - The company holds exclusive rights for the development, production, and commercialization of HLX701 in China (excluding Taiwan), Southeast Asia, the Middle East, and North Africa [1] Group 2: Mechanism of Action - HLX701 works by binding to CD47 on tumor cells, effectively blocking the inhibitory CD47 anti-phagocytic signal, which promotes macrophage phagocytosis of tumor cells and enhances anti-tumor activity [1] - Preclinical studies indicate that HLX701 can synergize with various drugs, including chemotherapy agents, immune checkpoint inhibitors, epidermal growth factor receptor inhibitors, and anti-angiogenic drugs, suggesting potential for enhanced immune responses when used in combination with standard treatment regimens [1]

Core Viewpoint - The approval of the IND application for HLX701 in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer marks a significant advancement for the company in its clinical development pipeline [1][2]. Group 1: Product Overview - HLX701 is a SIRPα-Fc fusion protein licensed from FBD Biologics Limited, intended for the treatment of various advanced solid tumors [2]. - The company holds exclusive rights for the development, production, and commercialization of HLX701 in China (excluding Taiwan), Southeast Asia, the Middle East, and North Africa [2]. Group 2: Mechanism of Action - HLX701 functions by binding to CD47 on tumor cells, effectively blocking the inhibitory CD47 anti-phagocytic signal, which promotes macrophage phagocytosis of tumor cells and enhances anti-tumor activity [2]. - Preclinical studies indicate that HLX701 can synergize with various drugs, including chemotherapy agents, immune checkpoint inhibitors, epidermal growth factor receptor inhibitors, and anti-angiogenic drugs, suggesting potential for enhanced innate and adaptive immune responses when used in combination with standard treatment regimens [2].

Market Overview - The biopharmaceutical sector experienced a decline of 0.63% on January 20, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Tonghua Dongbao (600867) with a closing price of 8.81, up 2.20% on a trading volume of 319,000 shares and a turnover of 280 million yuan [1] - Wufan Bio (301393) closed at 55.20, up 1.81% with a trading volume of 22,900 shares and a turnover of 128 million yuan [1] - Kanghua Bio (300841) closed at 76.45, up 1.58% with a trading volume of 23,800 shares and a turnover of 183 million yuan [1] - Major decliners included: - Olin Bio (616889) closed at 25.98, down 3.88% with a trading volume of 87,000 shares and a turnover of 226 million yuan [2] - Junshi Bio (688180) closed at 35.29, down 3.42% with a trading volume of 119,400 shares and a turnover of 425 million yuan [2] - Ganli Pharma (603087) closed at 70.23, down 2.70% with a trading volume of 81,800 shares and a turnover of 577 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 335 million yuan from institutional investors, while retail investors experienced a net inflow of 128 million yuan [2] - The capital flow for specific stocks indicated: - Wanze Co. (000534) had a net inflow of 103 million yuan from institutional investors [3] - Watson Bio (300142) saw a net inflow of 40 million yuan from institutional investors [3] - Olin Bio (688319) had a net inflow of 17.96 million yuan from institutional investors [3]

Core Viewpoint - Junshi Biosciences (688180.SH) is currently experiencing a decline in stock price, closing at 35.29 yuan with a drop of 3.42%, indicating a state of being below its initial public offering (IPO) price [1] Fundraising and Financial Performance - Junshi Biosciences raised a total of 4.836 billion yuan from its IPO on July 15, 2020, with a net amount of 4.497 billion yuan after deducting issuance costs, exceeding the original plan by 1.797 billion yuan [1] - The company planned to raise 2.7 billion yuan for innovative drug research, industrialization projects, bank loan repayment, and working capital [1] - The company raised an additional 3.7765 billion yuan through a private placement of 70 million shares at 53.95 yuan per share in 2022, with a net amount of approximately 3.7448 billion yuan after costs [2] - The total funds raised by Junshi Biosciences from both public and private placements amount to 8.612 billion yuan [3] Profitability and Revenue Trends - From 2016 to 2024, Junshi Biosciences reported negative net profits, with figures ranging from -1.35 billion yuan to -23.88 billion yuan [3] - For the first three quarters of 2025, the company achieved a revenue of 1.806 billion yuan, reflecting a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an improvement from -927 million yuan in the previous year [3] - The net cash flow from operating activities for the same period was -343 million yuan, compared to -1.113 billion yuan in the previous year [3]

节目中，凯普生物常务副总经理管秩生的互动，更凸显了潮商精神的传承力量。管秩生提到，父亲身上的"红头船精神"——敢为天下先的勇气，正是父亲 1999年、2000年毅然投身生物科技领域的关键。这份勇于开拓、坚守初心的精神，正通过代际传承，成为凯普生物持续发展的内生动力。 1月18日晚，中央广播电视总台财经频道《对话·创新中国行》栏目以"千年潮商赓续新程"为主题重磅播出。凯普生物董事长管乔中受邀登台，围绕家乡情 怀、创业初心、技术创新与产业布局等核心话题，分享了凯普生物深耕生物科技领域的发展密码，展现了潮商精神的传承与升华，为生物科技行业高质量发 展提供了鲜活范本。 作为从潮州走出的优秀企业家，管乔中在节目中一句"回来就好，回来就好"的心声，引发了广泛情感共鸣。北京大学哲学社会科学一级教授、中央文史研究 馆馆员陈平原现场解读，这句简单的话语背后，蕴含着潮汕人漂洋过海、九死一生的创业艰辛，更承载着潮商对家乡的深厚眷恋与文化根脉。这份扎根故 土、心系桑梓的情怀，成为凯普生物发展路上的精神底色，也诠释了潮商"家国情怀、诚实守信"的核心特质。 在谈及创业成功的密码时，管乔中毫无保留地分享了三大核心要素：一是不懈努力，这是支 ...

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) has received the "High-tech Enterprise Certificate" from the Beijing Municipal Science and Technology Commission, which allows its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., to benefit from tax incentives for high-tech enterprises [1] Group 1 - The certificate number is GR202511004935, issued on December 2, 2025, and is valid for three years [1] - This recognition is a re-certification following the expiration of the previous certificate [1] - The company will enjoy a corporate income tax rate of 15% for the years 2025, 2026, and 2027 under the national tax incentive policy for high-tech enterprises [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its self-developed B023 cell injection [1] Group 1: Product Development - B023 cell injection is an innovative Class I biopharmaceutical developed and produced by Shanghai Pharmaceuticals Biotherapy, targeting locally advanced or metastatic solid tumors that are inoperable and have no effective treatment options after standard therapy failure [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) [1] - Human iNKT cells have TCR chains TCRvα24 and TCRvβ11, which recognize lipid antigens presented by MHC class I molecule CD1d [1] Group 2: Clinical Implications - CD1d is non-polymorphic in the population, allowing for the allogeneic application of iNKT cells without causing graft-versus-host disease (GvHD), making it a universal cell type [1]

Group 1 - The National Medical Products Administration (NMPA) accepted the market application for the first-class new drug BL-B01D1, which is indicated for recurrent or metastatic esophageal squamous cell carcinoma that has failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] - BL-B01D1 (Iza-bren) is a globally innovative dual-antibody ADC that blocks signals from EGFR and HER3 to tumor cells, inhibiting their proliferation and survival [1] - The drug's mechanism includes antibody-mediated endocytosis, which releases therapeutic payloads that induce genotoxic stress, ultimately leading to tumor cell death [1] Group 2 - In December 2023, the company entered into an exclusive licensing and collaboration agreement with Bristol-Myers Squibb (BMS) for the global development and commercialization of Iza-bren [2] - BMS will pay the company an upfront fee of $800 million, along with two milestone payments of $250 million each; additional payments could reach up to $7.1 billion based on development, registration, and sales milestones [2] - The total potential deal value could reach $8.4 billion, setting a record for the highest total price for a single drug licensing agreement in the ADC field [2] - Currently, there are only 10 biopharmaceutical new drugs approved for esophageal cancer treatment globally, with no ADCs approved yet; if approved, BL-B01D1 will be the first ADC for esophageal cancer treatment [2]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Pharmaceuticals Biologicals, has received the Clinical Trial Approval Notice from the National Medical Products Administration for its self-developed "B023 Cell Injection" [1] Group 1: Product Development - B023 Cell Injection is an innovative Class I biological product developed and produced by Shanghai Pharmaceuticals Biologicals, with the core component being invariant natural killer T cells (iNKT) [1] - The clinical intended use for B023 is for locally advanced or metastatic solid tumors that are inoperable and have failed standard treatments, with no effective treatment options available [1] - As of the announcement date, the project has accumulated research and development expenses of approximately 39.2584 million RMB [1] Group 2: Market Position - There are currently no other drugs on the global market with the same variety and indication as B023 Cell Injection [1]